CGTLive’s Weekly Rewind – October 6, 2023


Review top news and interview highlights from the week ending October 6, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. News and Expert Insights in Rare Cancer Cell Therapy for Rare Cancer Day

In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news and expert insights related to cell therapies in development for these indications.

2. Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas

The professor of medicine and pediatrics at Washington University in St. Louis discussed future challenges and exciting research in the sarcoma field.

3. Capricor Aligns With FDA on DMD Cell Therapy CAP-1002's Trial in Type-B Meeting

The company stated that based on the meeting, the trial’s primary end points will remain the same.

4. David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMD

The senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.

5. Rocket’s LAD-I Gene Therapy BLA Accepted for Priority Review

The therapy has a PDUFA date of March 31, 2024.

Related Videos
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
© 2024 MJH Life Sciences

All rights reserved.